Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04322643
Title Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Case Comprehensive Cancer Center
Indications

transitional cell carcinoma

Therapies

Durvalumab

Pembrolizumab

Avelumab

Nivolumab

Atezolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.